Evidence Explorer · MS-N238 · Botanical supplement · Supportive care · Appraised November 4, 2026
Two multicenter randomized trials found some nausea-related benefits from product-specific ginger regimens, but endpoints and timing differed and authoritative guidance still describes the overall literature as conflicting.
Evidence at a glance
Benefit signal: Product-specific acute or delayed nausea signals as an adjunct to antiemetics
Certainty: Low to moderate; two randomized trials with differing formulations and outcomes
Risk context: Gastrointestinal irritation, bleeding and gallbladder concerns; never a replacement for prescribed antiemetics
What was studied
In a dose-finding trial, 744 adults were randomized and 576 were evaluable. Ginger powder 0.5, 1.0 or 1.5 g/day was taken for six days starting three days before chemotherapy, alongside a 5-HT3 antagonist. All doses reduced day-1 nausea severity; 0.5 and 1.0 g produced the largest effects. Delayed nausea did not significantly improve.
A later trial randomized 103 chemotherapy-naïve adults to a standardized product providing 84 mg/day gingerols and shogaols or placebo for five days across three cycles. Nausea-related quality of life and delayed nausea favored ginger; acute nausea did not. No serious intervention-related adverse events were reported.
What this evidence cannot establish
The trials used different products, doses, timing and antiemetic backgrounds. The earlier trial did not control for chemotherapy emetogenicity and had substantial attrition from 744 randomized to 576 evaluable.
NCI PDQ continues to describe conflicting efficacy. Ginger does not replace guideline-concordant 5-HT3, NK1, dexamethasone or olanzapine-based prophylaxis when indicated.
Practical safety context
Ginger can cause reflux or abdominal discomfort and may increase bleeding risk, particularly with anticoagulants, thrombocytopenia or surgery. Concentrated supplements differ from culinary use.
Uncontrolled vomiting, inability to keep fluids down, dizziness, reduced urine or fever requires prompt oncology contact because dehydration and electrolyte problems can become serious.
Questions for the care team
- What emetogenic-risk regimen and standard antiemetic plan apply?
- Is the proposed ginger product standardized like either trial product?
- Do anticoagulation, low platelets, reflux or gallstones change the risk?
- How will acute and delayed nausea be tracked separately?
Funding and conflicts
Funding and conflicts varied across the two trials and were not fully verified here. The findings should be treated as formulation-specific rather than a class effect.
Sources
- Dose-finding randomized trial (PMID 21818642)
- Standardized ginger randomized trial (PMID 37699474)
- NCI PDQ: treatment-related nausea and vomiting
- Related Missing Script review: chemotherapy nausea and complementary approaches
Sources and publication status checked November 4, 2026. Last literature search: November 4, 2026; record appraisal: November 4, 2026.
For education, not personal medical advice. Research regimens are not personal prescriptions. Symptom, laboratory or biomarker changes do not establish tumor response, recurrence prevention or longer survival.
